EMEA-002096-PIP01-16-M03
Key facts
Invented name |
Rozlytrek
|
Active substance |
Entrectinib
|
Therapeutic area |
Oncology
|
Decision number |
P/0351/2021
|
PIP number |
EMEA-002096-PIP01-16-M03
|
Pharmaceutical form(s) |
|
Condition(s) / indication(s) |
Treatment of all conditions induded in the category of malignant neoplasms ( except haematopoietic and lymphoid tissue neoplasms)
|
Route(s) of administration |
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6169 79411 |
Decision type |
PM: decision on the application for modification of an agreed PIP
|